Speakers

Early agenda available! View Now

Distinguished Co-Chairs

Guy Donatiello

Senior Vice President, Intellectual Property
Endo Pharmaceuticals

Co-Chairs’ Opening Remarks

November 10, 2021 • 7:50 am

Pearl Siew

Senior Vice President and Head, Intellectual Property
Design Therapeutics

Co-Chairs’ Opening Remarks

November 10, 2021 • 7:50 am

Members of the Judiciary

U.S. District Court

Honorable Mitchell Goldberg

District Judge
United States District Court, Eastern District of Pennsylvania
(Visiting Judge, District of Delaware)

Spotlight on Delaware: District Court Judges Address Brand and Generic Concerns

November 9, 2021 • 4:45 pm

Honorable Maryellen Noreika

District Judge
United States District Court, District of Delaware

Spotlight on Delaware: District Court Judges Address Brand and Generic Concerns

November 9, 2021 • 4:45 pm

Honorable Mary Pat Thynge

Chief Magistrate Judge
District of Delaware

Track A | Understanding the Importance of Aligning Legal and Business Functions for Patent Litigation Planning

Track B | Practical Strategies and Tactics for Effective Settlement Negotiation

November 9, 2021 • 3:30 pm

Honorable Christopher J. Burke

Magistrate Judge
District of Delaware

Track A | The Business of Hatch-Waxman Litigation: A Global Approach

Track B | The Practice of Hatch-Waxman Litigation: Town Hall with the Magistrate Judges

November 9, 2021 • 2:30 pm

USPTO’s Patent Trial and Appeal Board (PTAB)

Honorable Jacqueline Wright Bonilla

Deputy Chief Administrative Patent Judge
Patent Trial & Appeal Board
USPTO

The PTAB Live! Practice, Policy, and Procedure in the New World of Pharmaceutical Patent Validity Challenges

November 10, 2021 • 9:00 am

Government Representatives from Key Agencies

Valencia Martin Wallace

Deputy Commissioner for Patents
U.S. Patent and Trademark Office

Diversity, Equity, and Inclusion: Implementing Change and Expanding Innovation

November 10, 2021 • 11:30 am

Maryll Toufanian

Director, Office of Generic Drug Policy
U.S. FDA

Analyzing the Effect of the Latest FDA Initiatives on Generic Drug Access and PIV Disputes

November 10, 2021 • 8:00 am

In-House Counsel

Andrew J. Allen

Senior Director, Legal Counsel
Dr. Reddy’s Laboratories

Written Description and Enablement: Defensive Strategies and Offensive Moves for §112 Rejections and Attacks

November 10, 2021 • 2:15 pm

Ryan M. Daniel

Chief Patent Counsel, Region North America
Fresenius Kabi USA, LLC

The Current State of Patent Eligibility Jurisprudence: Redefining What Is Patent-Eligible Subject Matter Post-American Axle v. Neapco

November 9, 2021 • 11:00 am

Stephanie Donahue

Senior Director, Patent Litigation
Sanofi- Aventis

Track A | Understanding the Importance of Aligning Legal and Business Functions for Patent Litigation Planning

Track B | Practical Strategies and Tactics for Effective Settlement Negotiation

November 9, 2021 • 3:30 pm

Henry H. Gu

VP, Head of Intellectual Property
Morphic Therapeutics

Track A | The Business of Hatch-Waxman Litigation: A Global Approach

Track B | The Practice of Hatch-Waxman Litigation: Town Hall with the Magistrate Judges

November 9, 2021 • 2:30 pm

James Kellerman

Senior Vice President, IP
Astellas Pharma US, Inc.

Forrester Liddle

Senior Director, Head of IP
Jounce Therapeutics

The Future of Obviousness: Objective Indicia of Nonobviousness and Obviousness-Type Double Patenting

November 9, 2021 • 1:30 pm

Josephine Liu

Global Head of IP Litigation
Sandoz

GSK v. Teva: Induced Infringement Liability the Fate of Section VIII Carve-Outs

November 9, 2021 • 9:30 am

Donna Meuth

Associate General Counsel, IP
Eisai

Track A | The Business of Hatch-Waxman Litigation: A Global Approach

Track B | The Practice of Hatch-Waxman Litigation: Town Hall with the Magistrate Judges

November 9, 2021 • 2:30 pm

Huong T. Nguyen

General Counsel
Fosun Pharma USA Inc.

Diversity, Equity, and Inclusion: Implementing Change and Expanding Innovation

November 10, 2021 • 11:30 am

Brian Stone

Associate General Counsel, Global Legal-Regulatory
Viatris

Analyzing the Effect of the Latest FDA Initiatives on Generic Drug Access and PIV Disputes

November 10, 2021 • 8:00 am

Lars Taavola

VP, Chief Intellectual Property Counsel
Mallinckrodt Pharmaceuticals

Track A | Understanding the Importance of Aligning Legal and Business Functions for Patent Litigation Planning

Track B | Practical Strategies and Tactics for Effective Settlement Negotiation

November 9, 2021 • 3:30 pm

Peter Waibel

Head, US Patent Litigation
Novartis Pharmaceuticals Corporation

Esteemed Faculty

Brian Anderson

Counsel
Polsinelli PC

To Stay or Not to Stay: Winning Strategies for Addressing Parallel Proceedings at the District Court and IPR

November 10, 2021 • 10:30 am

David L. Anstaett

Partner
Perkins Coie LLP

Written Description and Enablement: Defensive Strategies and Offensive Moves for §112 Rejections and Attacks

November 10, 2021 • 2:15 pm

David Blackburn

Director
NERA Economic Consulting

The Future of Obviousness: Objective Indicia of Nonobviousness and Obviousness-Type Double Patenting

November 9, 2021 • 1:30 pm

Michael A. Carrier

Distinguished Professor of Law
Rutgers Law

Think Tank on State and Federal Antitrust Initiatives: Commercial Considerations for Patent Settlements, Reverse Payments, and Emerging Legislation

November 10, 2021 • 1:15 pm

Dominick A. Conde

Partner
Venable LLP

To Stay or Not to Stay: Winning Strategies for Addressing Parallel Proceedings at the District Court and IPR

November 10, 2021 • 10:30 am

Steven M. Coyle

Partner
Cantor Colburn LLP

The Current State of Patent Eligibility Jurisprudence: Redefining What Is Patent-Eligible Subject Matter Post-American Axle v. Neapco

November 9, 2021 • 11:00 am

Neal Dahiya

SVP, Head of Litigation
Moderna

Diversity, Equity, and Inclusion: Implementing Change and Expanding Innovation

November 10, 2021 • 11:30 am

Jonathan Davies

Partner
Cooley LLP

The Current State of Patent Eligibility Jurisprudence: Redefining What Is Patent-Eligible Subject Matter Post-American Axle v. Neapco

November 9, 2021 • 11:00 am

Jay R. Deshmukh

Partner
Kasowitz Benson Torres

Forecasting the Future of Pharmaceutical Patent Litigation: Trends, Legal Analyses and Business Prognoses Post-Covid

November 9, 2021 • 8:15 am

Gerald J. Flattmann, Jr.

Partner
King & Spalding LLP

To Stay or Not to Stay: Winning Strategies for Addressing Parallel Proceedings at the District Court and IPR

November 10, 2021 • 10:30 am

Vishal C. Gupta

Partner
Steptoe & Johnson LLP

Track A | Understanding the Importance of Aligning Legal and Business Functions for Patent Litigation Planning

Track B | Practical Strategies and Tactics for Effective Settlement Negotiation

November 9, 2021 • 3:30 pm

Elizabeth Holland

Partner
Goodwin Procter LLP

The Future of Obviousness: Objective Indicia of Nonobviousness and Obviousness-Type Double Patenting

November 9, 2021 • 1:30 pm

Andrei Iancu

Partner
Irell & Manella LLP
(Former Director, U.S. Patent and Trademark Office)

Forecasting the Future of Pharmaceutical Patent Litigation: Trends, Legal Analyses and Business Prognoses Post-Covid

November 9, 2021 • 8:15 am

Kurt Karst

Director
Hyman, Phelps & McNamara PC

Analyzing the Effect of the Latest FDA Initiatives on Generic Drug Access and PIV Disputes

November 10, 2021 • 8:00 am

Noah M. Leibowitz

Partner
Dechert LLP

Track A | Understanding the Importance of Aligning Legal and Business Functions for Patent Litigation Planning

Track B | Practical Strategies and Tactics for Effective Settlement Negotiation

November 9, 2021 • 3:30 pm

Jonathan D.J. Loeb Ph.D.

Partner
Dechert LLP

The Ethical Practice of Paragraph IV Litigation: New Developments Impacting Professional Responsibility in the Hatch-Waxman Arena

November 10, 2021 • 4:15 pm

Alejandro Menchaca

Shareholder
McAndrews, Held & Malloy, Ltd.

The Current State of Patent Eligibility Jurisprudence: Redefining What Is Patent-Eligible Subject Matter Post-American Axle v. Neapco

November 9, 2021 • 11:00 am

Dr. Christine Siegwarth Meyer

Managing Director, Chair of IP
NERA Economic Consulting

Think Tank on State and Federal Antitrust Initiatives: Commercial Considerations for Patent Settlements, Reverse Payments, and Emerging Legislation

November 10, 2021 • 1:15 pm

Robert C. Millonig

Director
Sterne, Kessler, Goldstein & Fox P.L.L.C.

The Future of Obviousness: Objective Indicia of Nonobviousness and Obviousness-Type Double Patenting

November 9, 2021 • 1:30 pm

John J. Molenda

Partner
Steptoe & Johnson LLP

The PTAB Live! Practice, Policy, and Procedure in the New World of Pharmaceutical Patent Validity Challenges

November 10, 2021 • 9:00 am

Gregory A. Morris

Partner
Honigman LLP

The PTAB Live! Practice, Policy, and Procedure in the New World of Pharmaceutical Patent Validity Challenges

November 10, 2021 • 9:00 am

Michael K. Nutter

Partner
Winston & Strawn LLP

Track A | The Business of Hatch-Waxman Litigation: A Global Approach

Track B | The Practice of Hatch-Waxman Litigation: Town Hall with the Magistrate Judges

November 9, 2021 • 2:30 pm

Edward D. Pergament

Partner
Pergament & Cepeda LLP

To Stay or Not to Stay: Winning Strategies for Addressing Parallel Proceedings at the District Court and IPR

November 10, 2021 • 10:30 am

Adam L. Perlman

Partner
Latham & Watkins LLP

Track A | Understanding the Importance of Aligning Legal and Business Functions for Patent Litigation Planning

Track B | Practical Strategies and Tactics for Effective Settlement Negotiation

November 9, 2021 • 3:30 pm

James Peterka

Partner
Locke Lord LLP

GSK v. Teva: Induced Infringement Liability the Fate of Section VIII Carve-Outs

November 9, 2021 • 9:30 am

Adam Poff

Partner
Young Conaway Stargatt & Taylor, LLP

Track A | The Business of Hatch-Waxman Litigation: A Global Approach

Track B | The Practice of Hatch-Waxman Litigation: Town Hall with the Magistrate Judges

November 9, 2021 • 2:30 pm

Kevin S. Prussia

Partner
Wilmer Cutler Pickering Hale and Dorr LLP

Written Description and Enablement: Defensive Strategies and Offensive Moves for §112 Rejections and Attacks

November 10, 2021 • 2:15 pm

William A. Rakoczy

Founding Partner
Rakoczy Molino Mazzochi Siwik LLP

GSK v. Teva: Induced Infringement Liability the Fate of Section VIII Carve-Outs

November 9, 2021 • 9:30 am

Simon Roberts

Partner
Hogan Lovells

Forecasting the Future of Pharmaceutical Patent Litigation: Trends, Legal Analyses and Business Prognoses Post-Covid

November 9, 2021 • 8:15 am

Melanie R. Rupert

Partner, Global Co-Chair of Talent Development
Paul Hastings LLP

Track A | The Business of Hatch-Waxman Litigation: A Global Approach

Track B | The Practice of Hatch-Waxman Litigation: Town Hall with the Magistrate Judges

November 9, 2021 • 2:30 pm

Emily Savas

Partner
Locke Lord LLP

Written Description and Enablement: Defensive Strategies and Offensive Moves for §112 Rejections and Attacks

November 10, 2021 • 2:15 pm

Michael Sitzman

US Chair, Life Sciences Patent Litigation
DLA Piper

GSK v. Teva: Induced Infringement Liability the Fate of Section VIII Carve-Outs

November 9, 2021 • 9:30 am

Jeanna M. Wacker

Partner
Kirkland & Ellis LLP

Written Description and Enablement: Defensive Strategies and Offensive Moves for §112 Rejections and Attacks

November 10, 2021 • 2:15 pm

Elizabeth S. Weiswasser

Partner
Weil, Gotshal & Manges LLP

Spotlight on Delaware: District Court Judges Address Brand and Generic Concerns

November 9, 2021 • 4:45 pm

Alyson Wooten

Director
Berkeley Research Group LLC

Track A | Understanding the Importance of Aligning Legal and Business Functions for Patent Litigation Planning

Track B | Practical Strategies and Tactics for Effective Settlement Negotiation

November 9, 2021 • 3:30 pm

Vanessa Yen

Partner
King & Spalding LLP

GSK v. Teva: Induced Infringement Liability the Fate of Section VIII Carve-Outs

November 9, 2021 • 9:30 am